The Bottom Line
The Phase 3 RECITE trial demonstrates that in patients with gastrointestinal cancers and persistent chemotherapy-induced thrombocytopenia (CIT), romiplostim significantly increases the likelihood of maintaining chemotherapy dose intensity. Patients receiving romiplostim were nearly three times more likely to complete chemotherapy cycles without dose reductions, delays, or omissions compared to placebo (84% vs. 36%; RR 2.77, P<0.001).
Study Design
This international, double-blind, randomized, placebo-controlled Phase 3 trial enrolled 165 patients across 14 countries. Patients with persistent CIT were randomized 2:1 to receive:
- Romiplostim: Weekly subcutaneous injections adjusted (100 to 250×10⁹/L target) to maintain platelet counts.
- Placebo: Weekly subcutaneous injections.
Primary Endpoint: The absence of CIT-induced chemotherapy dose modifications (reduction, delay, omission, or discontinuation) in both the second and third planned chemotherapy cycles after enrollment.
Who Was Included
Adults with gastrointestinal cancers (75% colorectal, 13% gastroesophageal, 12% pancreatic) with persistent CIT (defined as platelets ≤85×10⁹/L on trial day 1). Patients were required to be receiving oxaliplatin-based multiagent regimens (e.g., FOLFOX, CAPOX, FOLFIRINOX). Majority of the patients had metastatic disease.
Who Was Excluded (Important for Clinical Practice)
- Thrombocytopenia from other causes (non-CIT).
- Hemoglobin <8 g/dL or ANC <1.5×10⁹/L.
- History of hematologic malignancy.
- Arterial thrombosis or significant cardiac abnormalities within the prior 4 months.
Key Results
| Outcome | Romiplostim (N=109) | Placebo (N=56) | Statistics |
| No CIT-induced dose modifications | 84% | 36% | RR 2.77 (P<0.001) |
| Median platelet nadir (x10⁹/L) | 87 | 58 | P=0.005 |
| Median time to platelet response | 1.1 weeks | 2.1 weeks | P<0.001 |
| Platelet response by week 4 | 96% | 66% | — |
| Grade ≥2 bleeding events | 4.0* | 7.6* | HR 0.53 (P=0.63) |
| Thromboembolic events | 2% | 0% | — |
*Rates per 100 patient-years.
Safety Considerations
- Adverse Events: Grade 3 or higher AEs occurred in 37% of the romiplostim group vs. 22% in the placebo group; however, these primarily reflected chemotherapy-related toxicities (neutropenia/anemia).
- Treatment-Related AEs: Reported in 12% of romiplostim patients vs. 7% in placebo. The most common were nausea and headache.
- Thromboembolism: Occurred in 2% (n=2) of the romiplostim group (one portal vein thrombosis, one splenic infarct) vs. 0% in the placebo group.
- MDS/Leukemia: No increased incidence of myelodysplastic syndrome or secondary hematologic cancers was noted during the study period.
Limitations to Consider
- Duration: The primary endpoint only evaluated dose modifications over two chemotherapy cycles.
- Population Specificity: Results are limited to gastrointestinal cancers and oxaliplatin-based regimens; extrapolation to other tumor types or gemcitabine-based regimens requires caution.
- Survival Data: While romiplostim improved dose intensity, the trial was not powered to show an improvement in overall survival or progression-free survival.
- Sample Size: The study was not large enough to fully characterize infrequent but serious risks, such as long-term marrow fibrosis or rare thrombotic events.
Clinical Implications
For the medical oncologist, CIT has historically been a “wait and see” complication that forced dose de-escalation. RECITE provides high-level evidence that romiplostim is an effective supportive care intervention to maintain relative dose intensity in GI oncology. While it did not show a statistically significant reduction in bleeding (likely due to low baseline event rates), the primary benefit lies in the preservation of the planned chemotherapy schedule.